Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future

Cancers

卷:13

Matthias Ocker¹  Sebastian Stintzing²  Daniel Neureiter³  Christian Mayr⁴  Tobias Kiesslich⁴ 

[1] Department of Gastroenterology (Campus Benjamin Franklin), Charité University Medicine Berlin, 10117 Berlin, Germany;

[2] Division of Hematology, Oncology, and Tumor Immunology (Campus Charité Mitte), Medical Department, Charité University Medicine Berlin, 10117 Berlin, Germany;

[3] Institute of Pathology, Paracelsus Medical University, University Hospital Salzburg (SALK), 5020 Salzburg, Austria;

[4] Institute of Physiology and Pathophysiology, Paracelsus Medical University, 5020 Salzburg, Austria;

关键词: hepatocellular carcinoma;    immunotherapy;    immune checkpoint inhibitors;    locoregional treatment;   

DOI  :  10.3390/cancers13071558

来源: DOAJ

【 摘 要 】

Background: Hepatocellular carcinoma (HCC) still represents a human tumor entity with very limited therapeutic options, especially for advanced stages. Here, immune checkpoint modulating drugs alone or in combination with local ablative techniques could open a new and attractive therapeutic “door” to improve outcome and response rate for patients with HCC. Methods: Published data on HCC experimental to pre-(clinical) treatment strategies from standard of care to novel immunomodulatory concepts were summarized and discussed in detail. Results: Overall, our knowledge of the role of immune checkpoints in HCC is dramatically increased in the last years. Experimental and pre-clinical findings could be translated to phase 1 and 2 clinical trials and became standard of care. Local ablative techniques of HCC could improve the effectivity of immune checkpoint inhibitors in situ. Conclusions: This review demonstrates the importance of immunomodulatory treatment strategies of HCC, whereby the “best treatment code” of immune checkpoint drugs, combination with ablative techniques and of timing must be evaluated in coming clinical trials.

【 授权许可】

Unknown